Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01263769 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
A Phase 2 study of Kidney Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT01263769: Completed Phase 2 study of Kidney Cancer, sponsored by M.D. Anderson Cancer Center.
NCT01263769 is a Phase 2 study of Kidney Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 39 participants, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01263769, a Phase 2 study of Kidney Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if axitinib can help to control kidney cancer. The safety of this drug will also be studied.
Primary Outcome
Objective response rate is defined as Complete Response (CR)+ Partial Response (PR) and evaluated when CT abdomen is done after 12 weeks of treatment. Per Response Evaluation Criteria in Solid Tumors Criteria ( RECIST v1.0) Complete Response (CR) is complete disappearance of renal mass; and, Partial Response (PR) is \>= 30% decrease in the largest diameter (LD) of the renal mass taking as reference the baseline largest diameter.
Conditions Studied
Interventions
- DRUG Axitinib
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2011-02 |
| Est. Completion | 2023-06-05 |
| Phase | Phase 2 |
What the finished NCT01263769 record still lists
NCT01263769 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 1 intervention - of which Axitinib is the first listed.
NCT01263769 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01263769 about?
NCT01263769 is a clinical study titled "Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)". The goal of this clinical research study is to learn if axitinib can help to control kidney cancer. The safety of this drug will also be studied.
What is the current status of trial NCT01263769?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2011-02. Estimated completion is 2023-06-05.
What conditions does trial NCT01263769 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT01263769?
The interventions under investigation include: Axitinib (DRUG).
Who is sponsoring clinical trial NCT01263769?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01263769 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01263769's enrollment target sits among peer trials
39 36th of 60 higher than 24 of 60 other Kidney Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia